-
1.发明申请METHODS FOR TREATING OBESITY EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITIONS THEREOF 有权用于治疗服用SGLT2抑制剂的药物的方法及其组合物公开(公告)号：US20120077739A1
公开(公告)日：2012-03-29
申请号：US13310097
申请日：2011-12-02
IPC分类号： A61K38/18 , A61P3/04 , A61K31/7034
CPC分类号： A61K31/00 , A61K31/70 , A61K31/7004 , A61K31/7034 , A61K45/06 , Y10S514/909
摘要： Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof.
摘要翻译： 提供了用于治疗哺乳动物受试者或患者的肥胖症或引起体重减轻的方法，其中将单独或任选与另一种抗肥胖剂组合的治疗有效量的SGLT2抑制剂施用于哺乳动物受试者或患者。 此外，提供了药物组合物，其包含单独或与另一种抗肥胖剂组合的SGLT2抑制剂及其药学上可接受的载体。
-
公开(公告)号：US08088743B2
公开(公告)日：2012-01-03
申请号：US12053508
申请日：2008-03-21
IPC分类号： A61K31/70
CPC分类号： A61K31/00 , A61K31/70 , A61K31/7004 , A61K31/7034 , A61K45/06 , Y10S514/909
摘要： Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof.
摘要翻译： 提供了用于治疗哺乳动物受试者或患者的肥胖症或引起体重减轻的方法，其中将单独或任选与另一种抗肥胖剂组合的治疗有效量的SGLT2抑制剂施用于哺乳动物受试者或患者。 此外，提供了药物组合物，其包含单独或与另一种抗肥胖剂组合的SGLT2抑制剂及其药学上可接受的载体。
-
3.发明申请Methods for Treating Obesity Employing an SGLT2 Inhibitor and Compositions Thereof 有权使用SGLT2抑制剂及其组合物治疗肥胖症的方法公开(公告)号：US20080234367A1
公开(公告)日：2008-09-25
申请号：US12053508
申请日：2008-03-21
IPC分类号： A61K31/351 , A61P3/10
CPC分类号： A61K31/00 , A61K31/70 , A61K31/7004 , A61K31/7034 , A61K45/06 , Y10S514/909
摘要： Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof.
摘要翻译： 提供了用于治疗哺乳动物受试者或患者的肥胖症或引起体重减轻的方法，其中将单独或任选与另一种抗肥胖剂组合的治疗有效量的SGLT2抑制剂施用于哺乳动物受试者或患者。 此外，提供了药物组合物，其包含单独或与另一种抗肥胖剂组合的SGLT2抑制剂及其药学上可接受的载体。
-
公开(公告)号：US08883743B2
公开(公告)日：2014-11-11
申请号：US13310097
申请日：2011-12-02
IPC分类号： A61K31/70 , A61K31/00 , A61K31/7034 , A61K45/06 , A61K31/7004
CPC分类号： A61K31/00 , A61K31/70 , A61K31/7004 , A61K31/7034 , A61K45/06 , Y10S514/909
摘要： Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof.
摘要翻译： 提供了用于治疗哺乳动物受试者或患者的肥胖症或引起体重减轻的方法，其中将单独或任选与另一种抗肥胖剂组合的治疗有效量的SGLT2抑制剂施用于哺乳动物受试者或患者。 此外，提供了药物组合物，其包含单独或与另一种抗肥胖剂组合的SGLT2抑制剂及其药学上可接受的载体。
-
公开(公告)号：US20100256153A1
公开(公告)日：2010-10-07
申请号：US12748140
申请日：2010-03-26
IPC分类号： A61K31/4985 , A61K31/403 , A61K31/40 , A61P9/12 , A61P3/06 , A61P9/00
CPC分类号： A61K31/40 , A61K31/4985
摘要： The present invention relates to methods for preventing or reducing the risk of mortality by any means including, but not limited to, cardiovascular events in mammals, particularly humans, comprising administering a dipeptidyl peptidase 4 (DPP-IV) inhibitor to the mammal or human. In addition, the present invention relates to methods for preventing or reducing the risk of non-fatal myocardial infarction and/or non-fatal stroke in mammals, particularly humans, comprising administering a DPP-IV inhibitor to the mammal or human.
摘要翻译： 本发明涉及通过任何方式预防或降低死亡风险的方法，包括但不限于哺乳动物，特别是人类的心血管事件，包括向哺乳动物或人施用二肽基肽酶4（DPP-IV）抑制剂。 此外，本发明涉及用于预防或降低哺乳动物，特别是人类的非致命性心肌梗死和/或非致命性中风的风险的方法，包括向哺乳动物或人施用DPP-IV抑制剂。
-
-
-
-
搜索结果
5 条记录 (耗时 0.032 秒)
